www.fdanews.com/articles/122875-graft-versus-host-disease-failures-and-future-opportunities

Graft-Versus-Host Disease: Failures and Future Opportunities

December 10, 2009

In September 2009, Osiris Therapeutics, Inc. reported preliminary results from two Phase III trials evaluating its Prochymal product candidate for the treatment of acute graft-versus-host disease.
Seeking Alpha